author-photo

Elizabeth Stankevich

Regeneron

35

Papers

3112

Citations

Citation Trend

Filter By

Papers (29) Sort By

Journal Conference Others

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): data from the Phase 1 NSCLC expansion cohort

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and GM-CSF in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (1)
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis.

2021 Advances in Therapy
Show All
- Source
- Cite
- Save
Citations (0)
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (31)
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

2020 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (108)
A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (17)
1372TiPA phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)